Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE StudyMOLINA, Jean-Michel; ANDRADE-VILLANUEVA, Jaime; WIRTZ, Victoria et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 3, pp 323-332, issn 1525-4135, 10 p.Article

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients : 48 week efficacy and safety results of the CASTLE study. CommentaryTORTI, Carlo; MOLINA, Jean-Michel; RANG YANG et al.Lancet (British edition). 2008, Vol 372, Num 9639, issn 0140-6736, 604-606, 646-655 [13 p.]Article

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week resultsMURPHY, Robert L; SANNE, Ian; CAHN, Pedro et al.AIDS (London). 2003, Vol 17, Num 18, pp 2603-2614, issn 0269-9370, 12 p.Article